Five articles suggested by Yüksel Ürün
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.
He suggested following few must-read papers on X:
1.”Oncologists must weigh patient benefits, potential risks, and fairness in access.
Clear conversations about test limits and impacts are key to making informed, ethical decisions.”
Authors: Kathryn DeCarli, Angela Bradbury, Ana Maria Lopez, Polo Camacho, Monica S. Chatwal, Christopher R. Friese, Rachel Jimenez, Liza-Marie Johnson, Amy L. McGuire, Rebecca Spence and Jeffrey Peppercorn.
2.”Community oncologists face challenges interpreting complex molecular test reports to provide precise cancer care.
Molecular Tumor Boards (MTBs) and online decision tools help bridge knowledge gaps, ensuring access to expert insights and improving patient outcomes.”
Interpretation of Reports and Translation to Community Oncologists: An Overview of Approaches.
Authors: Carol J. Farhangfar, Kathryn F. Mileham and Antoinette R. Tan.
3.”Pharmacogenomics (PGx) testing transforms cancer care by tailoring treatment based on genetics.”
Authors: Nury M. Steuerwald, Sarah Morris, D. Grace Nguyen and Jai N. Patel.
4.”In MIBC, deleterious DDR gene alterations, especially ERCC2, show promise as markers for better response to cisplatin-based chemotherapy.
Patients with these alterations had higher rates of pathologic response, suggesting the potential for personalized NAC strategies in bladder cancer.”
Authors: Gopa Iyer, Catherine M. Tangen, Michal Sarfaty, Ashley M. Regazzi, I-Ling Lee, Megan Fong, Woonyoung Choi, Colin P.N. Dinney, Thomas W. Flaig, Ian M. Thompson Jr, Seth P. Lerner, David J. McConkey and Jonathan E. Rosenberg.
5.”While overtreatment of low-risk prostate cancer dropped, overtreatment in men with limited life expectancy and higher-risk prostate cancer rose, primarily through radiotherapy.
Reducing unnecessary treatment can prevent avoidable toxicities for those unlikely to benefit.”
Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era.
Authors: Timothy J. Daskivich, Michael Luu, John Heard, I-Chun Thomas, John T. Leppert.
For latest updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023